Patent ID: 11891445
Assignee: ABL BIO INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A  G | IPC A  C  G

Claim 0:
1. An isolated antibody specifically recognizing B7-H3 or its antigen-binding fragment,
wherein the antibody or antigen-binding fragment comprises (i) heavy chain complementarity determining regions of CDRH1, CDRH2 and CDRH3, and (ii) light chain complementarity determining regions of CDRL1, CDRL2 and CDRL3, and wherein,
(a) the CDRH1, CDRH2 and CDRH3 are SEQ ID NOs: 1, 5, and 10, respectively, and the CDRL1, CDRL2, and CDRL3 are SEQ ID NOs: 15, 20 and 25, respectively;
(b) the CDRH1, CDRH2 and CDRH3 are SEQ ID NOs: 2, 6, and 11, respectively, and the CDRL1, CDRL2, and CDRL3 are SEQ ID NOs: 16, 21 and 26, respectively;
(c) the CDRH1, CDRH2 and CDRH3 are SEQ ID NOs: 3, 7, and 12, respectively, and the CDRL1, CDRL2, and CDRL3 are SEQ ID NOs: 17, 22 and 27, respectively;
(d) the CDRH1, CDRH2 and CDRH3 are SEQ ID NOs: 1, 8, and 13, respectively, and the CDRL1, CDRL2, and CDRL3 are SEQ ID NOs: 18, 23 and 28, respectively;
(e) the CDRH1, CDRH2 and CDRH3 are SEQ ID NOs: 4, 9, and 14, respectively, and the CDRL1, CDRL2, and CDRL3 are SEQ ID NOs: 19, 24 and 29, respectively
(f) the CDRH1, CDRH2 and CDRH3 are SEQ ID NOs: 3, 68, and 12, respectively, and the CDRL1, CDRL2, and CDRL3 are SEQ ID NOs: 17, 22, and 27, respectively; or
(g) the CDRH1, CDRH2 and CDRH3 are SEQ ID NOs: 3, 68, and 12, respectively, and the CDRL1, CDRL2, and CDRL3 are SEQ ID NOs: 17, 69, and 27, respectively.